

# Every-2-Month Dosing and Administration of Long-Acting Cabotegravir + Rilpivirine for the Treatment of HIV-1

## Optional Oral Lead-in Therapy<sup>1</sup>

- The healthcare provider and patient may decide to use an oral lead-in with oral cabotegravir and oral rilpivirine prior to the initiation of CAB + RPV LA injections to assess tolerability.
- Alternatively, the healthcare provider and patient may decide to proceed directly to initiation injections without the use of the oral lead-in
- If the oral lead-in is used, the recommended dose is one 30-mg tablet of cabotegravir and one 25-mg tablet of rilpivirine, taken once daily with a meal, for approximately 1 month.
- The first initiation injection of CAB + RPV LA should begin on the last day of current antiretroviral therapy or oral lead-in (if used).

## CAB + RPV LA Every-2-Month Dosing Recommendations<sup>1</sup>

Drug	Optional Oral Lead-In* (at Least 28 Days)	Intramuscular (Gluteal) Initiation Injections <sup>†</sup>
	Month (at least 28 days) prior to starting injections	Initiate Injections <sup>‡</sup> at Month 1, Month 2, and then Every 2 Months Onwards (Starting at Month 4)
<b>Cabotegravir</b>	30 mg once daily with a meal	600 mg (3 mL)
<b>Rilpivirine</b>	25 mg once daily with a meal	900 mg (3 mL)

\* Optional oral therapy or current suppressive antiretroviral therapy should be continued until the day the first injection is administered.

<sup>†</sup> For the every-2-month injection dosing schedule, Initiation Injections are administered Month 1 and Month 2 and Continuation Injections are administered every 2 months onwards (starting Month 4).

<sup>‡</sup> Given on the last day of current antiretroviral therapy or oral lead-in if used.

- Adherence to the every-2-month injection schedule is strongly recommended. Patients who miss a scheduled injection visit should be clinically assessed to ensure resumption of therapy remains appropriate.<sup>1</sup>
- CAB LA and RPV LA IM injections are given at separate gluteal injection sites at the same visit.<sup>1</sup>

**Abbreviations:** CAB, cabotegravir; IM, Intramuscular injection; RPV, rilpivirine.

**Reference:** 1. ViiV Healthcare. Global Data Sheet for Cabotegravir. Version 03. April 15, 2020.

# Every-2-Month Dosing and Administration of Long-Acting Cabotegravir + Rilpivirine for the Treatment of HIV-1


## Planned Missed Injections<sup>1</sup>

If a patient plans to miss a scheduled injection visit by more than 7 days, CAB + RPV oral tablets (one 30-mg tablet of cabotegravir and one 25-mg tablet of rilpivirine) can be used for up to 2 months to replace 1 missed injection visit, or any fully suppressive oral antiretroviral regimen may be used until injections are resumed. For oral therapy durations greater than 2 months, an alternative oral therapy is recommended.

Injections should be re-initiated by administering 600 mg (3-mL) cabotegravir and 900 mg (3-mL) rilpivirine injections 1 month apart for 2 consecutive months, then the every-2-month administration schedule may resume. Resumption of injections is based on the time since the missed target treatment date as shown in the table below.

The first dose of oral therapy should be taken approximately 2 months after the last injection dose of CAB + RPV LA and continued until the day injection dosing is restarted.

### EXAMPLE: Use of Oral Therapy with Oral CAB + RPV for 2 Months to Cover a Planned Missed Injection Visit



## Unplanned Missed Injections<sup>1</sup>

If a scheduled every-2-month injection visit is missed or delayed by more than 7 days and oral therapy has not been taken in the interim, clinically reassess the patient to determine if resumption of injection dosing remains appropriate.

## Resumption of Injections After Planned Missed Injections<sup>1</sup>

Time Since MISSED Injection Date	Injection Dosing Recommendation
≤ 1 month	Continue with every-2-month (3-mL, 600-mg CAB LA and 900-mg RPV LA) IM injections dosing schedule as soon as possible
> 1 month	Reinitiate the patient with initial 3-mL, 600-mg cabotegravir and 900-mg rilpivirine intramuscular injections: 2 initiation injections 1 month apart, then every-2-months thereafter

For more information



CLICK FOR **ViiV US**  
**Medical Portal**

Some information contained in this response may not be included in the approved Prescribing information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Please note that reports of adverse events in the published literature often lack causality assessments and may contain incomplete information; therefore, conclusions about causality generally cannot be drawn. In order for ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872. Please consult the attached Prescribing Information. This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive.

**Abbreviations:** CAB, cabotegravir; IM, Intramuscular injection; RPV, rilpivirine.

**Reference:** 1. ViiV Healthcare. Global Data Sheet for Cabotegravir. Version 03. April 15, 2020.